Press Releases

July 27, 2017

For more information, contact
Glenn E. Martin at (520) 818-8582

WEED, Inc. Acquires La Veta, CO Facility Property for Cannabis Genomic Study

Wholly-owned subsidiary, Sangre AgroTech, begins construction of state-of-the-art Cannabis genomic scientific research facility

TUCSON, AZ / ACCESSWIRE / July 27, 2017 / WEED, Inc. (OTC PINK: BUDZ) (the “Company,” or ” WEED”), fka United Mines, Inc., a current alternative reporting public company, announced today their acquisition of property in La Veta, CO for development of its Cannabis genomic research facility, the Sangre Bioscience Center. La Veta, located in southern Colorado’s Spanish Peaks region, is the new home for Sangre AT, LLC (dba “Sangre AgroTech”), the Company’s wholly-owned subsidiary. Sangre AgroTech has begun its 5-Year, $15+ million Cannabis Genomic Study to complete a global genomic classification of the Cannabis plant genus.

The site includes a 10,000+ sq. ft. building that will house the genomic research facility, a 4,000+ square foot building for plant product analytics and plant product extraction, a 3,500 sq. ft. corporate office center, and 25 RV slots with full water and electric, which will be converted to a series of small research pods. This acquisition provides Sangre AgroTech with the opportunity to expand its research mission through the construction of additional research laboratories and cloning facilities.

Doug Brgoch, the Mayor of La Veta, CO, said, “I cannot tell you how happy I am to have Sangre AgroTech join our community. The locating of the company to La Veta, I believe, will mean a great boost for the Town’s economy and financial stability for our municipal government. The local school district will benefit through increased enrollment and taxes, and Huerfano County will also feel a positive impact. This enterprise is exactly what I hoped would come to our Town. I can’t wait to see what evolves.”

Mary Williams, Sangre AgroTech’s Vice President of Operations, stated, “All of us at Sangre AgroTech are thrilled to join the La Veta business community. We are excited to continue the work we’ve begun on sequencing and annotation of the Cannabis genome as we develop new therapies for chronic pain, epilepsy, cancer, PTSD, chronic head injury, and Crohn’s disease, among others. Sangre looks forward to being a good neighbor to our friends in La Veta and making a positive impact on the town.”

About WEED, Inc.

WEED, Inc. (OTC PINK: BUDZ) is a USA-based alternative reporting public company. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. subsidiaries in foreign locations. For additional information about WEED, Inc., please visit

About Sangre AT, LLC

Sangre AT, LLC (dba “Sangre AgroTech”) is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre AgroTech, please visit

Forward-Looking Statements:

This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could,” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays, and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

For more information, contact:
Glenn E. Martin at (520) 818-8582


Stay Informed

Sign up to receive our latest news and announcements